Tags Archive Navigation
icon
-
Media ReleaseNovartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
-
Media ReleaseNovartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Media ReleaseLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
-
Media ReleaseNovartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media ReleaseNovartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
StoryQ&A: Addressing unmet needs for people living with PNH, a rare and chronic blood disorder
-
Landing PageDiseases
-
StoryDiscover how inflammation could fan the flames of cancer
-
StoryDoing the right thing is good business
-
StoryStriving to vanquish leukemia
-
StoryTake a visual tour of medicines that target RNA
-
StoryNovartis and UC Berkeley take on “undruggable” proteins in new collaboration